Role of CD10 Marker in Differentiating Malignant Thyroid Neoplasms from Benign Thyroid Lesions (Immunohistochemical & Histopathological Study)

Overview

Journal Open Access Maced J Med Sci

Specialty General Medicine

Date 2019 Jan 5

PMID 30607179

Citations 3

Authors

Samia Mohamed Gabal

Mostafa Mohamed Salem

Rasha Ramadan Mostafa

Shaimaa Mohamed Abdelsalam

Affiliations

Soon will be listed here.

Abstract

Background: CD10 was initially recognised as a cell-surface antigen expressed by acute lymphoblastic leukaemias, and hence it's early designation as Common Acute Lymphoblastic Leukemia Antigen (CALLA). Also, it has been proven to be reactive in various non-lymphoid cells and tissue and different types of neoplasms.

Aim: To evaluate the immunohistochemical expression of CD10 in malignant thyroid neoplasms and different benign lesions and to assess whether CD10 can be used as a malignancy marker in thyroid pathology or not.

Material And Methods: A total of 83 archived, formalin fixed, paraffin embedded tissue blocks of 83 cases of malignant thyroid neoplasms and different benign lesions. The samples were immunohistochemically analysed for CD10 expression. A p-value of less than 0.05 was considered statistically significant.

Results: CD10 was expressed in 91% of the studied malignant thyroid neoplasms and 58% of benign thyroid lesions. It was expressed in 26 of 28 (92.9%) conventional papillary carcinomas, ten of 10 (100%) follicular variants of papillary carcinoma, seven of nine (77.8%) minimally invasive follicular carcinomas, two of three (66.7%) widely invasive follicular carcinomas, and seven of 7 (100%) undifferentiated carcinomas, seven of 11 (66.7%) adenomatous nodules and eight of 15 (53.3%) follicular adenomas. No statistically significant correlations were detected between CD10 expression and patients' age, sex, lymph node metastasis, tumour stage and capsular invasion.

Conclusion: CD10 shows strong sensitivity (91.2%) and moderate specificity (42.3%) in the diagnosis of malignancy overall and shows strong sensitivity (86.4%) and moderate specificity (42.3%) in the diagnosis of malignancy in the follicular-patterned lesions. So, CD10 might be useful in differentiating malignant from benign thyroid lesions (good positive test) and in the diagnosis of follicular variant of papillary carcinoma.

Citing Articles

Diagnostic significance of CD10 marker to differentiate colorectal adenocarcinoma from adenomatous polyp: A pathological correlation.

Dehini G, Ghorbani H, Khafri S, Shirvani J, Hosseini A, Sadr Mohararpur S Caspian J Intern Med. 2024; 15(2):228-233.

PMID: 38807719 PMC: 11129067. DOI: 10.22088/cjim.15.2.228.

Targeting CD10 on B-Cell Leukemia Using the Universal CAR T-Cell Platform (UniCAR).

Mitwasi N, Arndt C, Loureiro L, Kegler A, Fasslrinner F, Berndt N Int J Mol Sci. 2022; 23(9).

PMID: 35563312 PMC: 9105388. DOI: 10.3390/ijms23094920.

Prognostic Implications of CD10 and CD15 Expression in Papillary Thyroid Carcinoma.

Oh E, Bychkov A, Cho H, Kim T, Bae J, Lim D Cancers (Basel). 2020; 12(6).

PMID: 32486143 PMC: 7352591. DOI: 10.3390/cancers12061413.

References

Millar E, Waldron S, Spencer A, Braye S . CD10 positive thyroid marginal zone non-Hodgkin lymphoma. J Clin Pathol. 2000; 52(11):849-50. PMC: 501601. DOI: 10.1136/jcp.52.11.849. View

Chu P, Arber D . Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol. 2000; 113(3):374-82. DOI: 10.1309/8VAV-J2FU-8CU9-EK18. View

Hundahl S, Cady B, Cunningham M, Mazzaferri E, McKee R, Rosai J . Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation.... Cancer. 2000; 89(1):202-17. DOI: 10.1002/1097-0142(20000701)89:1<202::aid-cncr27>3.0.co;2-a. View

Williams E . Guest Editorial: Two Proposals Regarding the Terminology of Thyroid Tumors. Int J Surg Pathol. 2001; 8(3):181-183. DOI: 10.1177/106689690000800304. View

Sahoo S, Hoda S, Rosai J, DeLellis R . Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Am J Clin Pathol. 2001; 116(5):696-702. DOI: 10.1309/6D9D-7JCM-X4T5-NNJY. View

Beesley M, McLaren K . Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology. 2002; 41(3):236-43. DOI: 10.1046/j.1365-2559.2002.01442.x. View

Tomoda C, Kushima R, Takeuti E, Mukaisho K, Hattori T, Kitano H . CD10 expression is useful in the diagnosis of follicular carcinoma and follicular variant of papillary thyroid carcinoma. Thyroid. 2003; 13(3):291-5. DOI: 10.1089/105072503321582105. View

Lloyd R, Erickson L, Casey M, Lam K, Lohse C, Asa S . Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol. 2004; 28(10):1336-40. DOI: 10.1097/01.pas.0000135519.34847.f6. View

Mehrotra P, Okpokam A, BouHaidar R, Johnson S, Wilson J, Davies B . Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology. 2004; 45(5):493-500. DOI: 10.1111/j.1365-2559.2004.01978.x. View

10.

Vasko V, Gaudart J, Allasia C, Savchenko V, Di Cristofaro J, Saji M . Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma. Eur J Endocrinol. 2004; 151(6):779-86. DOI: 10.1530/eje.0.1510779. View

11.

de Matos P, Ferreira A, de Oliveira Facuri F, Assumpcao L, Metze K, Ward L . Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology. 2005; 47(4):391-401. DOI: 10.1111/j.1365-2559.2005.02221.x. View

12.

Ito Y, Yoshida H, Tomoda C, Miya A, Kobayashi K, Matsuzuka F . Galectin-3 expression in follicular tumours: an immunohistochemical study of its use as a marker of follicular carcinoma. Pathology. 2005; 37(4):296-8. DOI: 10.1080/00313020500169545. View

13.

Scognamiglio T, Hyjek E, Kao J, Chen Y . Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol. 2006; 126(5):700-8. DOI: 10.1309/044V-86JN-2W3C-N5YB. View

14.

Yegen G, Demir M, Ertan Y, Nalbant O, Tuncyurek M . Can CD10 be used as a diagnostic marker in thyroid pathology?. Virchows Arch. 2008; 454(1):101-5. DOI: 10.1007/s00428-008-0698-2. View

15.

Minamimoto R, Senda M, Jinnouchi S, Yoshida T, Nakashima R, Nishizawa S . [Assessment of diagnostic criteria for FDG-PET cancer screening program according to the interpretation of FDG-PET and combined examination]. Kaku Igaku. 2009; 46(2):73-93. View

16.

Bahadir B, Behzatoglu K, Bektas S, Bozkurt E, Ozdamar S . CD10 expression in urothelial carcinoma of the bladder. Diagn Pathol. 2009; 4:38. PMC: 2780995. DOI: 10.1186/1746-1596-4-38. View

17.

Duggal R, Rajwanshi A, Gupta N, Vasishta R . Interobserver variability amongst cytopathologists and histopathologists in the diagnosis of neoplastic follicular patterned lesions of thyroid. Diagn Cytopathol. 2011; 39(4):235-41. DOI: 10.1002/dc.21363. View

18.

Matos L, Giglio A, Matsubayashi C, Farah M, Del Giglio A, da Silva Pinhal M . Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn Pathol. 2012; 7:97. PMC: 3523001. DOI: 10.1186/1746-1596-7-97. View

19.

Mokhtari M, Ameri F . Diagnostic value of CD-10 marker in differentiating of papillary thyroid carcinoma from benign thyroid lesions. Adv Biomed Res. 2014; 3:206. PMC: 4219203. DOI: 10.4103/2277-9175.143241. View

20.

Mechtersheimer G, Moller P . Expression of the common acute lymphoblastic leukemia antigen (CD10) in mesenchymal tumors. Am J Pathol. 1989; 134(5):961-5. PMC: 1879890. View